Pulse Biosciences, Inc. (PLSE) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Instruments & Supplies Branche. Der Hauptsitz des Unternehmens ist in Miami, CA, United States. Der aktuelle CEO ist Paul Arthur LaViolette.
PLSE hat IPO-Datum 2016-05-18, 75 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $1.37B.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
